Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose...

Area of Science:

• Pharmacology
• Neurology
• Oncology

Background:

• Chemotherapy-induced neuropathic pain (CINP) is a common, severe side effect of cancer treatment.
• Existing analgesics are often ineffective for managing CINP.
• Tetrodotoxin (TTX) is being investigated as a novel therapeutic option for pain management.

Purpose of the Study:

• To evaluate the safety and efficacy of different doses of Tetrodotoxin (TTX) for chemotherapy-induced neuropathic pain (CINP).
• To identify an optimal dose of TTX for further clinical investigation in patients with CINP.
• To assess the impact of TTX on patient-reported pain scores and quality of life.

Main Methods:

• A randomized, double-blind, placebo-controlled, dose-finding study involving 125 patients with taxane- or platinum-related CINP.
• Patients received subcutaneous placebo or one of four TTX doses (7.5 µg BID, 15 µg BID, 30 µg QD, 30 µg BID) for four consecutive days.
• Primary outcome: change in Numeric Pain Rating Scale (NPRS) score from Day 21-28 post-treatment. Secondary outcomes: quality of life measures (SF-36, CIPN20) and adverse events.

Main Results:

• No statistically significant difference in mean NPRS scores between groups due to small sample size and placebo responders.
• Cumulative responder analysis indicated a significant difference from placebo for the 30 µg BID TTX cohort across multiple time points (p=0.027 for 10-day rolling average).
• The 30 µg BID TTX group showed significant improvements in several SF-36 and CIPN20 quality of life subscales compared to placebo. Most adverse events were mild/moderate, with oral paresthesia and hypoesthesia being most common.

Conclusions:

• The 30 µg BID dose of Tetrodotoxin (TTX) demonstrated promising efficacy trends for chemotherapy-induced neuropathic pain (CINP), particularly in responder analysis and quality of life improvements.
• While overall mean pain scores did not reach statistical significance, the 30 µg BID dose warrants further investigation for CINP treatment.
• Tetrodotoxin (TTX) appears to be generally well-tolerated, with manageable adverse events, supporting its potential as a future therapeutic agent for CINP.